Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0
Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

The board of directors (“Board”) of Neuralstem, Inc. (the “Company”) was notified by Tianjin Pharmaceuticals Group International Holdings Co., LTD (“Tianjin”) that Binxian Wei is being appointed to replace Xi Chen as the director appointee of the Company’s Series A 4.5% Convertible Preferred Stock (“Series A Stock”) effective February 5, 2019. Tianjin is the sole shareholder of the Company’s Series A Stock. Mr. Wei will serve as a Class III director until the Company’s 2020 annual shareholder meeting or until such time as he resigns or is removed.

There are no family relationships among Mr. Wei and any of our executive officers or directors.

As compensation for their services on the Board, Mr. Wei will participate in the Company’s non-executive board compensation plan as described in the Company’s Current Report on Form8-K filed on June 27, 2017.

About Neuralstem, Inc. (NASDAQ:CUR)

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.